$ADVM
Adverum Biotechnologies, Inc. Stock $advm

$advm Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000162828020012332 Filed on August 10, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.60M	$7.130M
YoY Change	48.67%	-22.33%
% of Gross Profit
Research & Development	$19.18M	$8.970M
YoY Change	113.79%	-20.05%
% of Gross Profit
Depreciation & Amortization	$1.300M	$420.0K
YoY Change	209.52%	-34.38%
% of Gross Profit
Operating Expenses	$29.78M	$16.10M
YoY Change	84.91%	-21.05%
Operating Profit	-$29.78M	-$16.10M
YoY Change	84.91%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$575.0K	$1.148M
YoY Change	-49.91%	5.32%
Pretax Income	-$29.20M	-$14.95M
YoY Change	95.32%	-20.52%
Income Tax
% Of Pretax Income
Net Earnings	-$29.20M	-$14.95M
YoY Change	95.27%	-20.5%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.36
Diluted Earnings Per Share	-$0.36	-$234.5K
COMMON SHARES
Basic Shares Outstanding	80.23M shares
Diluted Shares Outstanding	80.23M shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$280.1M	$177.6M
YoY Change	57.71%	-24.39%
Cash & Equivalents	$27.36M	$97.81M
Short-Term Investments	$252.8M	$79.80M
Other Short-Term Assets	$2.500M	$2.900M
YoY Change	-13.79%	-3.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$282.7M	$180.6M
YoY Change	56.56%	-24.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.47M	$6.097M
YoY Change	350.48%	143.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.00K	$174.0K
YoY Change	-89.08%	-84.18%
Total Long-Term Assets	$48.50M	$29.32M
YoY Change	65.38%	237.05%
TOTAL ASSETS
Total Short-Term Assets	$282.7M	$180.6M
Total Long-Term Assets	$48.50M	$29.32M
Total Assets	$331.2M	$209.9M
YoY Change	57.79%	-14.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.37M	$740.0K
YoY Change	1300.95%	-64.76%
Accrued Expenses	$10.90M	$9.400M
YoY Change	15.96%	11.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.25M	$10.15M
YoY Change	109.42%	-10.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$101.0K	$191.0K
YoY Change	-47.12%	-48.1%
Total Long-Term Liabilities	$101.0K	$191.0K
YoY Change	-47.12%	-48.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.25M	$10.15M
Total Long-Term Liabilities	$101.0K	$191.0K
Total Liabilities	$48.61M	$32.14M
YoY Change	51.24%	145.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$437.1M	-$350.0M
YoY Change	24.89%
Common Stock	$720.3M	$528.5M
YoY Change	36.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$282.6M	$177.7M
YoY Change
Total Liabilities & Shareholders Equity	$331.2M	$209.9M
YoY Change	57.79%	-14.89%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$29.20M	-$14.95M
YoY Change	95.27%	-20.5%
Depreciation, Depletion And Amortization	$1.300M	$420.0K
YoY Change	209.52%	-34.38%
Cash From Operating Activities	-$16.90M	-$11.59M
YoY Change	45.82%	2.11%
INVESTING ACTIVITIES
Capital Expenditures	-$3.120M	-$2.490M
YoY Change	25.3%	1456.25%
Acquisitions
YoY Change
Other Investing Activities	-$85.51M	-$34.09M
YoY Change	150.84%	-326.36%
Cash From Investing Activities	-$88.63M	-$36.60M
YoY Change	142.16%	-345.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.740M	1.880M
YoY Change	45.74%	889.47%
NET CHANGE
Cash From Operating Activities	-16.90M	-11.59M
Cash From Investing Activities	-88.63M	-36.60M
Cash From Financing Activities	2.740M	1.880M
Net Change In Cash	-102.8M	-46.31M
YoY Change	121.96%	-1338.24%
FREE CASH FLOW
Cash From Operating Activities	-$16.90M	-$11.59M
Capital Expenditures	-$3.120M	-$2.490M
Free Cash Flow	-$13.78M	-$9.100M
YoY Change	51.43%	-18.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001501756
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36579
	dei	Entity Registrant Name EntityRegistrantName	Adverum Biotechnologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5258327
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 Saginaw Drive,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	656-9323
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	ADVM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80656651	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27359000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65897000	USD
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	252780000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	100138000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2542000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9835000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	282681000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	175870000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20011000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20963000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27466000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000	USD
CY2020Q2	us-gaap	Assets Assets	331176000	USD
CY2019Q4	us-gaap	Assets Assets	222727000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10367000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4103000	USD
CY2020Q2	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	6666000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4221000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4034000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21254000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19408000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27258000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28214000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	101000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	48613000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	47770000	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	720288000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	560704000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-598000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-725000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-437135000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-385029000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	282563000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	331176000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	222727000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19177000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8970000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33928000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19101000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10598000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7132000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19638000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12708000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	29775000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	16102000	USD
	us-gaap	Operating Expenses OperatingExpenses	53566000	USD
	us-gaap	Operating Expenses OperatingExpenses	31809000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-29775000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16102000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53566000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31809000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	575000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1148000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1460000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2366000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-29200000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-14954000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52106000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29443000	USD
CY2020Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	194000	USD
CY2019Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	20000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	140000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	23000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	41000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	38000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28965000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14938000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51979000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29382000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80229000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63740000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77010000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63429000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3409000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	303953000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	332000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140873000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9650000	USD
CY2020Q1	advm	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod	7000	shares
CY2020Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	1922000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4785000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	51000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2487000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	475000	USD
CY2020Q2	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	121000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	41000	USD
CY2020Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	194000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	201167000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-29200000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	282563000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1762000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	162000	USD
CY2019Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	504000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	42000	USD
CY2019Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14489000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	188143000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2626000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2312000	USD
CY2019Q2	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	700000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	163000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
CY2019Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	20000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-14954000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	177740000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52106000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29443000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1896000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	846000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8194000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4388000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	429000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	414000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-38000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7298000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-589000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	18000	USD
	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-952000	USD
	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-1078000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6962000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-924000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2507000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2029000	USD
	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-769000	USD
	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	1084000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30523000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24805000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	319690000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	70549000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	160900000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	41385000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6748000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7328000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4683000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-159370000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33847000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	163000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1511000	USD
	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	140822000	USD
	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	134000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12101000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2474000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2043000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1204000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	475000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	56000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	151355000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38538000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57141000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66896000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155948000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28358000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98807000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2391000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	291000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-437100000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2020Q2	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	22298000	USD
CY2020Q2	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2020Q2	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	0	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	22298000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	252622000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	189000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	252780000	USD
CY2019Q4	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	51391000	USD
CY2019Q4	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2019Q4	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	3000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	51388000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	100117000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	28000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	100138000	USD
CY2020Q2	advm	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears	55700000	USD
CY2020Q2	advm	Other Than Temporary Impaired Investments Available For Sale Securities OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities	0	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35751000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32876000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8285000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7992000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27466000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1900000	USD
CY2020Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	USD
CY2020Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3248000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4055000	USD
CY2020Q2	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	1656000	USD
CY2019Q4	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	1973000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1197000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2607000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	565000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2636000	USD
CY2020Q2	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	6666000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.20
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8995000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3501000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.35
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1953000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	576000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.11
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9967000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.49
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3115000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.89
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4785000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2626000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8194000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4388000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10660000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9266000	shares

Files In Submission

Name	View Source	Status
0001628280-20-012332-index-headers.html	Edgar Link	pending
0001628280-20-012332-index.html	Edgar Link	pending
0001628280-20-012332.txt	Edgar Link	pending
0001628280-20-012332-xbrl.zip	Edgar Link	pending
advm-20200630.htm	Edgar Link	pending
advm-20200630.xsd	Edgar Link	pending
advm-20200630ex311.htm	Edgar Link	pending
advm-20200630ex312.htm	Edgar Link	pending
advm-20200630ex321.htm	Edgar Link	pending
advm-20200630ex322.htm	Edgar Link	pending
advm-20200630_cal.xml	Edgar Link	unprocessable
advm-20200630_def.xml	Edgar Link	unprocessable
advm-20200630_htm.xml	Edgar Link	completed
advm-20200630_lab.xml	Edgar Link	unprocessable
advm-20200630_pre.xml	Edgar Link	unprocessable
exhibit101laurentfisch.htm	Edgar Link	pending
exhibit102laurentfisch.htm	Edgar Link	pending
exhibit103leonepatters.htm	Edgar Link	pending
exhibit104leonepatters.htm	Edgar Link	pending
exhibit105leonepatters.htm	Edgar Link	pending
exhibit106arnon-employ.htm	Edgar Link	pending
exhibit1072006eip-equi.htm	Edgar Link	pending
exhibit1082014eip.htm	Edgar Link	pending
exhibit1092017induceme.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image01.jpg	Edgar Link	pending
image012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADVM
Adverum Biotechnologies, Inc. Stock $advm

2020 Q2 Form 10-Q Financial Statement

#000162828020012332 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM Adverum Biotechnologies, Inc. Stock $advm

2020 Q2 Form 10-Q Financial Statement

#000162828020012332 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM
Adverum Biotechnologies, Inc. Stock $advm